Profile data is unavailable for this security.
About the company
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Company’s products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndrome’76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.
- Revenue in CNY (TTM)220.55m
- Net income in CNY8.35m
- Incorporated1981
- Employees295.00
- LocationShanghai Hile Bio-Technology Co LtdNo. 6720Jinhai Highway, Fengxian DistrictSHANGHAI 200021ChinaCHN
- Phone+86 2 160890892
- Fax+86 2 160890800
- Websitehttp://www.hile-bio.com
More ▼
Mergers & acquisitions
| Acquired company | 603718:SHH since announced | Transaction value |
|---|---|---|
| Shaanxi Reshine Biotechnology Co Ltd | 22.57% | 128.89m |
Data delayed at least 15 minutes, as of Nov 13 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hunan Fangsheng Pharmaceutical Co Ltd | 1.76bn | 272.96m | 5.36bn | 1.69k | 19.54 | 3.36 | -- | 3.04 | 0.6244 | 0.6244 | 4.05 | 3.63 | 0.5513 | 1.43 | 6.70 | 1,044,835.00 | 8.34 | 5.39 | 14.83 | 9.37 | 69.28 | 66.91 | 15.12 | 8.95 | 0.4736 | -- | 0.3161 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Shouyao Holdings Co Ltd | 4.03m | -209.50m | 5.48bn | 185.00 | -- | 6.37 | -- | 1,360.17 | -1.41 | -1.41 | 0.0271 | 5.79 | 0.0038 | 0.1616 | 5.03 | 21,779.19 | -19.57 | -37.24 | -21.64 | -42.63 | 95.48 | 96.03 | -5,199.60 | -2,251.77 | 7.06 | -- | 0.0087 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Hainan Huluwa Pharmaceutical Grop Co Ltd | 1.82bn | 112.88m | 5.56bn | 2.47k | 49.23 | 4.81 | -- | 3.05 | 0.2821 | 0.2821 | 4.55 | 2.89 | 0.6323 | 2.49 | 3.22 | 737,841.70 | 4.09 | 5.81 | 6.24 | 9.78 | 53.91 | 58.01 | 6.48 | 7.03 | 0.7573 | 12.48 | 0.5316 | 21.74 | 25.75 | 14.13 | 24.29 | 1.16 | 46.37 | -- |
| Shanghai Haixin Group Co Ltd | 841.27m | 178.76m | 5.56bn | 760.00 | 41.53 | 1.70 | -- | 6.61 | 0.1481 | 0.1481 | 0.697 | 3.62 | 0.1607 | 5.09 | 6.89 | 1,106,933.00 | 4.06 | 2.68 | 4.52 | 3.06 | 52.44 | 44.55 | 25.25 | 11.17 | 3.01 | -- | 0.0077 | 36.10 | -17.88 | 1.48 | 1.20 | 4.19 | -10.27 | 13.18 |
| Sinotherapeutics Inc | 449.12m | 109.57m | 5.58bn | 260.00 | 50.89 | 4.51 | -- | 12.42 | 0.2417 | 0.2417 | 0.9907 | 2.73 | 0.3228 | 2.50 | 5.20 | 1,727,366.00 | 7.88 | -- | 8.54 | -- | 53.66 | -- | 24.40 | -- | 7.95 | -- | 0.00002 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
| Shanghai Hile Bio-Technology Co Ltd | 220.55m | 8.35m | 5.75bn | 295.00 | 755.40 | 4.52 | -- | 26.07 | 0.0116 | 0.0116 | 0.337 | 1.93 | 0.1379 | 1.26 | 2.06 | 747,619.90 | 0.0221 | 1.73 | 0.0278 | 2.47 | 48.68 | 50.44 | 0.1606 | 10.37 | 2.92 | -- | 0.0504 | 23.89 | -19.76 | -1.11 | -48.30 | 24.17 | -41.32 | 23.47 |
| Guizhou Sanli Pharmaceutical Co Ltd | 2.11bn | 328.87m | 5.98bn | 2.28k | 18.72 | 3.73 | -- | 2.83 | 0.7798 | 0.7798 | 5.05 | 3.91 | 0.8372 | 2.90 | 4.48 | 925,761.20 | 13.32 | 12.39 | 19.88 | 16.72 | 69.37 | 70.45 | 15.91 | 16.31 | 1.62 | -- | 0.2373 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
Data as of Nov 13 2024. Currency figures normalised to Shanghai Hile Bio-Technology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.77m | 0.28% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 1.51m | 0.23% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 847.80k | 0.13% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 704.40k | 0.11% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 327.10k | 0.05% |
| Western Asset Management Co. Pty Ltd.as of 30 Jun 2024 | 230.10k | 0.04% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 127.40k | 0.02% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2024 | 54.89k | 0.01% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 37.80k | 0.01% |
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 21.30k | 0.00% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
